real-time news and commentary for investors
Monday, Apr 29
Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription...
Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription performance. According to data, the drug has already garnered nearly 8% of the multiple sclerosis market through the week ended April 19, with prescriptions up 120% over the prior week. By comparison, Novartis' (NVS) Gilenya saw a market share drop to 6%. RBC sees performance on track to meet quarterly sales expectations.